Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 5.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 112.50
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Presentation

27 Nov 2023 10:00

RNS Number : 7512U
Eco Animal Health Group PLC
27 November 2023

ECO Animal Health Group plc

(''ECO" or the "Group") (AIM: EAH)

Investor Presentation covering Interim Results

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's interim results for the period ended 30 September 2023.

The online presentation will take place on Wednesday 29 November at 3.00pm UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

To register for the event, please click here

A video recording of the presentation will be available shortly afterwards here

Contacts:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

IFC Advisory

Graham Herring

Zach Cohen

020 3934 6630

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAUBAKRONUAURA
Date   Source Headline
7th Mar 200611:47 amRNSSAR 3 - Lawrence Plc
13th Feb 20067:01 amRNSTrading Statement
26th Jan 200611:47 amRNSSAR 3 - Lawrence Plc
12th Dec 20057:01 amRNSInterim Results
23rd Nov 200512:58 pmRNSSAR 3 - Lawrence Plc
27th Oct 200510:56 amRNSSAR 3 - Lawrence Plc
5th Sep 200510:52 amRNSSAR 3 - Lawrence Plc
29th Jul 20057:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.